Zelira Therapeutics, an Australia-based medical cannabis company, has partnered with the Parkinson’s Foundation to learn more about patients’ usage and understanding of medical cannabis and hemp-derived treatments. Zelira and the organization are developing a survey looking at current use and perceived benefits of medical cannabis among those…
Elevated blood levels of the liver enzyme gamma-glutamyltransferase (GGT), a marker for liver disease, was found to be associated with an increased risk of Parkinson’s disease in Korean women and a lower risk in Korean men, a large-scale study  found.
Kevin Schaefer hadn’t been in an airport since he was 4 years old, so he had been looking forward to flying from his home in Cary, North Carolina, to Anaheim, California, in June for the 2019 Cure SMA Conference. As it turned out, his experience didn’t go as expected.
Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein —…
Bone marrow stem cells treated with fasudil and administered via the nose (intranasal) to mice in a model of Parkinson’s disease led to evidence of better motor abilities and a reduced of dopaminergic neurons,  a recent study from China reports. These results suggest that fasudil’s use and intranasal delivery…
The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…
People who develop Parkinson’s disease before the age of 50 may have been born with the defective brain cells responsible for causing the illness, a study suggests. These results also reveal that a medicine, which is already approved by the U.S. Food and Drug Administration (FDA) for treating…
People who live less than 50 meters (about 54 yards) from major roads or 150 meters (164 yards) from a highway have a higher risk of developing Parkinson’s disease or other neurodegenerative disorders, according to a Canadian study. Meanwhile, green spaces such as parks seem to offer protection and lower…
The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to target a brain region critical for motor functions — the globus pallidus — as a way to lessen motor symptoms in Parkinson’s disease patients who still show impairments after medication.
A new small molecule called synucleozid can prevent cells from producing the Parkinson’s-associated protein alpha-synuclein by inhibiting its translation from RNA, a study shows. The study, “Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA,” was published in…
Get regular updates to your inbox.
